Why are GLP-1 receptor agonists in short supply?

Department of Health and Social Care. Medicine Supply Notification MSN/2022/080 Semaglutide (Ozempic®). https://www.dispensingdoctor.org/wp-content/uploads/2022/10/MSN_2022_080_-Semaglutide-Ozempic%C2%AE-1mg-injection.pdf Accessed 14 October 2022

Department of Health and Social Care. Medicine Supply Notification MSN/2022/079 Dulaglutide (Trulicity®). https://www.dispensingdoctor.org/wp-content/uploads/2022/10/MSN_2022_079-dulagtulide-all-strengths.pdf Accessed 14 October 2022

Pharmaceutical Services Negotiating Committee, Medicine Supply Notification 30 September 2022. https://psnc.org.uk/our-news/medicine-supply-notification-semaglutide-ozempic-1mg-0-74ml-solution-for-injection-3ml-pre-filled-disposable-device/ Accessed 14 October 2022

Beba H, Ranns C, Hambling C, Diggle J, Brown P. PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity. Diabetes Primary Care 2022;24(5). Available online athttps://diabetesonthenet.com/wp-content/uploads/PCDS-GLP-1-RA-shortage-statement.pdf Accessed 14 October 2022

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022.A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022 on-line ahead of print. https://doi.org/10.1007/s00125-022-05787-2

Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Clinical Practice Guidelines 2022; 26: 923-1049. https://doi.org/10.1016/j.eprac.2022.08.002

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline [NG28]. https://www.nice.org.uk/guidance/ng28 (Last updated version June 2022) Accessed 14 October 2022